You are receiving this message since your browser does not support Java Script or you have Java Scripts disabled. The following disclaimer is provided as an alternative to the information that would normally be seen on your monitor when you click on a link to a non-federal site.

"You are now leaving the NIDDK website. The NIDDK is not responsible for the content of web pages found on this linked website. Links to nonfederal organizations are provided solely as a service to our users. These links do not indicate an endorsement of these organizations by NIDDK or the federal government."

Type 1 Diabetes Special Statutory Funding Program

Clinical Studies Recruiting Type 1 Diabetes Patients and Family Members

ISLET TRANSPLANTATION

Clinical Islet Transplantation Consortium (CIT) : The goal of the CIT05 studies is to determine the proportion of subjects who are insulin independent at 75 ± 5 days following one islet cell infusion among subjects treated with an experimental islet transplant immunosuppression regimen which includes rituximab and excludes tacrolimus.
Study Names:Strategies to Improve Long Term Islet Graft Survival, B-Lymphocyte Immunotherapy in Islet Transplantation, Efficacy of Islet after Kidney Transplantation , Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes, Islet Transplantation in Type 1 Diabetes with LEA29Y Maintenance Therapy, Islet Transplantation in Type 1 Diabetes


Back to Clinical Studies Recruiting Type 1 Diabetes Patients and Family Members

Last Updated: June 30, 2008

General Inquiries may be addressed to:
Office of Communications and Public Liaison
NIDDK, NIH
Building 31, Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560 USA
For information about NIDDK programs: 301.496.3583